Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eupraxia Pharmaceuticals

3.48
+0.19005.78%
Volume:33.61K
Turnover:115.35K
Market Cap:124.76M
PE:-4.55
High:3.49
Open:3.38
Low:3.38
Close:3.29
Loading ...

Company Profile

Company Name:
Eupraxia Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
33
Office Location:
2067 Cadboro Bay Road,Suite 201,Victoria,British Columbia,Canada
Zip Code:
V8R 5G4
Fax:
- -
Introduction:
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Directors

Name
Position
James A. Helliwell
Chief Executive Officer and Director
Simon Pimstone
Chairman of the Board and Director
John Montalbano
Director
Michael Wilmink
Director
Paul Geyer
Director
Richard M. Glickman
Director

Shareholders

Name
Position
James A. Helliwell
Chief Executive Officer and Director
Bruce Cousins
Chief Financial Officer and President
Amanda Malone
Chief Scientific Officer
Paul Brennan
Chief Business Officer